CinPhloro Pharma

Year Invested/Status: 2016/Active

Motivation: Irritable bowel syndrome (IBS) is one of the most common reasons for a referral to a gastroenterologist at 40%[1]. All currently approved therapies for this chronic and debilitating condition provide sub-optimal treatment for patients and providers presenting a significant unmet medical need.

Lead Program(s): CIN-103 is a modified, pulsatile-release formulation of phloroglucinol designed for sustained symptomatic relief of patients suffering from IBS-D progressing into Phase 2. CIN-103 has secured strong intellectual property for it’s unique formulation and delivery properties.

Pre-Clinical

Phase 1

Phase 2

Phase 3

CIN-103
IBS - D

Sources:
[1] Zaman A. Irritable bowel syndrome. Clin Cornerstone. 2002;4(4):22-33. doi: 10.1016/s1098-3597(02)90003-7. PMID: 12739324.

INVESTOR INQUIRIES

CAREER INQUIRIES

GENERAL INQUIRIES